Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies

Author(s): Riccardo Pofi, Francesca Di Mario, Antonietta Gigante, Edoardo Rosato, Andrea M. Isidori, Antonio Amoroso, Rosario Cianci, Biagio Barbano

Journal Name: Current Drug Metabolism

Volume 17 , Issue 5 , 2016

Become EABM
Become Reviewer


Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.

Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.

Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.

Keywords: Chronic kidney disease, diabetes mellitus, diabetic nephropathy, end stage renal disease, novel therapies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 24 March, 2016
Page: [497 - 502]
Pages: 6
DOI: 10.2174/138920021705160324165553
Price: $65

Article Metrics

PDF: 65
PRC: 1